Use of bisphosphonates to improve the durability of total joint replacements

Journal of the American Academy of Orthopaedic Surgeons

Volumn 14, Issue 4, 2006, Pages 215-225

  Shanbhag, Arun S ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BMP2 PROTEIN, HUMAN; BONE DENSITY CONSERVATION AGENT; BONE MORPHOGENETIC PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA;

BED REST; BONE DEVELOPMENT; BONE REGENERATION; DRUG EFFECT; HUMAN; KNEE ARTHROPLASTY; METABOLISM; OSTEOLYSIS; OSTEOPOROSIS; PROSTHESIS FAILURE; REVIEW;

ARTHROPLASTY, REPLACEMENT, KNEE; BED REST; BONE DENSITY CONSERVATION AGENTS; BONE MORPHOGENETIC PROTEINS; BONE RESORPTION; DIPHOSPHONATES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OSSEOINTEGRATION; OSTEOGENESIS; OSTEOPOROSIS; PROSTHESIS FAILURE; TRANSFORMING GROWTH FACTOR BETA;

EID: 33746223260     PISSN: 1067151X     EISSN: None     Source Type: Journal    
DOI: 10.5435/00124635-200604000-00003     Document Type: Review

References (67)

1. Friedman RJ, Black J, Galante JO, Jacobs JJ, Skinner HB: Current concepts in orthopaedic biomaterials and implant fixation. Instr Course Lect 1994;43:233-255.
2. Shanbhag AS, Rubash HE: Wear: The basis of particle disease in total hip arthroplasty. Tech Orthop 1994;8:269-274.
3. Sinha RK, Shanbhag AS, Maloney WJ, Hasselman CT, Rubash HE: Osteolysis: Cause and effect. Instr Course Lect 1998;47:307-320.
4. Schmalzried TP, Jasty M, Harris WH: Periprosthetic bone loss in total hip arthroplasty: Polyethylene wear debris and the concept of the effective joint space. J Bone Joint Surg Am 1992;74:849-863.
5. Goldring SR, Schiller AL, Roelke M, Rourke CM, O'Neil DA, Harris WH: The synovial-like membrane at the bone-cement interface in loose total hip replacements and its proposed role in bone lysis. J Bone Joint Surg Am 1983;65:575-584.
6. Kim KJ, Rubash HE, Wilson SC, D'Antonio JA, McClain EJ: A histologic and biochemical comparison of the interface tissues in cementless and cemented hip prostheses. Clin Orthop Relat Res 1993;287:142-152.
7. Chiba J, Rubash HE, Kim KJ, Iwaki Y: The characterization of cytokines in the interface tissue obtained from failed cementless total hip arthroplasty with and without femoral osteolysis. Clin Orthop Relat Res 1994;300: 304-312.
8. Dorr LD, Bloebaum R, Emmanual J, Meldrum R: Histologic, biochemical, and ion analysis of tissue and fluids retrieved during total hip arthroplasty. Clin Orthop Relat Res 1990;261:82-95.
9. Shanbhag AS, Jacobs JJ, Black J, Galante JO, Glant TT: Cellular mediators secreted by interfacial membranes obtained at revision total hip arthroplasty. J Arthroplasty 1995;10:498-506.
10. Wright TM, Goodman SB: Implant Wear: The Future of Total Joint Replacement. Rosemont, IL: American Academy of Orthopaedic Surgeons, 1996.
11. McKellop H, Shen FW, Lu B, Campbell P, Salovey R: Development of an extremely wear-resistant ultra high molecular weight polyethylene for total hip replacements. J Orthop Res 1999;17:157-167.
12. Premnath V, Bellare A, Merrill EW, Jasty M, Harris WH: Molecular rearrangements in ultra high molecular weight polyethylene after irradiation and long-term storage in air. Polymer 1999;40:2215-2229.
13. Allen M, Law F, Rushton N: The effects of diamond-like carbon coatings on macrophages, fibroblasts and osteoblast-like cells in vitro. Clin Mater 1994;17:1-10.
14. Schwarz EM, Campbell D, Totterman S, Boyd A, O'Keefe RJ, Looney RJ: Use of volumetric computerized tomography as a primary outcome measure to evaluate drug efficacy in the prevention of peri-prosthetic osteolysis: A 1-year clinical pilot of etanercept vs. placebo. J Orthop Res 2003;21:1049-1055.
15. Rodan GA, Martin TJ: Therapeutic approaches to bone diseases. Science 2000;289:1508-1514.
16. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R: Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998;339:947-952.
17. Davis JC Jr, Huang F, Maksymowych W: New therapies for ankylosing spondylids: Etanercept, thalidomide, and pamidronate. Rheum Dis Clin North Am 2003;29:481-494.
18. Fleisch H, Russell RG, Francis MD: Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969;165:1262-1264.
19. Rodan GA, Fleisch HA: Bisphosphonates: Mechanisms of action. J Clin Invest 1996;97:2692-2696.
20. Fleisch H: Bisphosphonates in Bone Disease, ed 2. New York, NY: Parthenon Publishing Group, 1995.
21. Azuma Y, Sato H, Que Y, et al: Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone 1995;16:235-245.
22. Reynolds JJ, Minkin C, Morgan DB, Spycher D, Fleisch H: The effect of two diphosphonates on the resorption of mouse calvaria in vitro. Calcif Tissue Res 1972;10:302-313,
23. Zimolo Z, Wesolowski G, Rodan GA: Acid extrusion is induced by osteoclast attachment to bone: Inhibition by alendronate and calcitonin. J Clin Invest 1995;96:2277-2283.
24. Sato M, Grasser W, Endo N, et al: Bisphosphonate action: Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991;88:2095-2105.
25. Fisher JE, Rogers MJ, Halasy JM, et al: Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A 1999;96:133-138.
26. van Beek ER, Cohen LH, Leroy IM, Ebetino FH, Lowik CW, Papapoulos SE: Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 2003;33:805-811.
27. van beek E, Lowik C, van der Pluijm G, Papapoulos S: The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 1999;14:722-729.
28. Muhlbauer RC, Bauss F, Schenk R, et al: BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991;6:1003-1011.
29. Luekman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13:581-589.
30. Shanbhag AS, Hasselman CT, Rubash HE: The John Charnley Award. Inhibition of wear debris mediated osteolysis in a canine total hip arthroplasty model. Clin Orthop Relat Res 1997; 344:33-43.
31. Horowitz SM, Algan SA, Purdon MA: Pharmacologic inhibition of particulate-induced bone resorption. J Biomed Mater Res 1996;31:91-96.
32. Millett PJ, Allen MJ, Bostrom MP: Effects of alendronate on particle-induced osteolysis in a rat model. J Bone Joint Surg Am 2002;84:236-249.
33. Thadani PJ, Waxman B, Sladek E, Barmada R, Gonzalez MH: Inhibition of particulate debris-induced osteolysis by alendronate in a rat model. Orthopedics 2002;25:59-63.
34. von Knoch M, Wedemeyer C, Pingsmann A, et al: The decrease of particle-induced osteolysis after a single dose of bisphosphonate. Biomaterials 2005; 26:1803-1808.
35. Lyons AR, Owen JE, Freedholm DA, et al: Effect of alendronate on periprosthetic bone mass. Transactions of the 10th Combined Meeting of the Orthopaedic Association of the English Speaking World, Auckland, New Zealand, February 1-6, 1998, p 209.
36. Rubash HE, Dorr LD, Jacobs JJ, et al: Does alendronate inhibit the progression of periprosthetic osteolysis? Trans Orthop Res Soc 2004;29:1888.
37. Mosekilde L, Thomson JS, Mackey MS, Phipps RJ: Treatment with risedronate or alendronate prevents hind-limb immobilization-induced loss of bone density and strength in adult female rats. Bone 2000;27:639-645.
38. Goodship AE, Lawes TJ, Green J, Eldridge JD, Kenwright J: The use of bisphosphonates to inhibit mechanically related bone loss in aseptic loosening of hip prostheses. Trans Orthop Res Soc 1998;23:2.
39. Venesmaa PK, Kroger HP, Miettinen HJ, Jurvelin JS, Suomalainen OT, Alhava EM: Monitoring of periprosthetic BMD after uncemented total hip arthroplasty with dual-energy X-ray absorptiometry: A 3-year follow-up study. J Bone Miner Res 2001;16:1056-1061.
40. Venesmaa PK, Kroger HP, Miettinen HJ, Jurvelin JS, Suomalainen OT, Alhav EM: Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: A prospective randomized study. J Bone Miner Res 2001;16:2126-2131.
41. Soininvaara TA, Jurvelin JS, Miettinen HJ, Suomalainen OT, Alhava EM, Kroger PJ: Effect of alendronate on periprosthetic bone loss after total knee arthroplasty: A one-year, randomized, controlled trial of 19 patients. Calcif Tissue Int 1001,71:472-477.
42. Astrand J, Aspenberg P: Alendronate did not inhibit instability-induced bone resorption: A study in rats. Acta Orthop Scand 1999;70:67-70.
43. Astrand J, Aspenberg P: Reduction of instability-induced bone resorption using bisphosphonates: High doses are needed in rats. Acta Orthop Scand 2002;73:24-30.
44. Astrand J, Skripitz R, Skoglund B, Aspenberg P: A rat model for testing pharmacologic treatments of pressure-related bone loss. Clin Orthop Relat Res 2003;409:296-305.
45. Ryd L, Albrektsson BE, Carlsson L, et al: Roentgen stereophotogrammetric analysis as a predictor of mechanical loosening of knee prostheses. J Bone Joint Surg Br 1995;77:377-383.
46. Frenkel SR, Jaffe WL, Valle CD, et al: The effect of alendronate (Fosamax) and implant surface on bone integration and remodeling in a canine model. J Biomed Mater Res 2001;58:645-650.
47. Peter CP, Cook WO, Nunamaker DM, Provost MT, Seedor JG, Rodan GA: Effect of alendronate on fracture healing and bone remodeling in dogs. J Orthop Res 1996;14:74-79.
48. Hilding M, Ryd L, Toksvig-Larsen S, Aspenberg P: Clodronate prevents prosthetic migration: A randomized radiostereometric study of 50 total knee patients. Acta Orthop Scand 2000;71:553-557.
49. Astrand J, Aspenberg P: Systemic alendronate prevents resorption of necrotic bone during revascularization: A bone chamber study in rats. BMC Musculoskelet Disord 2002;3:19.
50. Aspenberg P, Astrand J: Bone allografts pretreated with a bisphosphonate are not resorbed. Acta Orthop Scand 2002;73:20-23.
51. Shanbhag AS, May D, Cha C, Hasselman CT, Rubash HE: Enhancing net bone formation in canine total hip components with bisphosphonates. Trans Orthop Res Soc 1999;44:255.
52. von Knoch F, Cho MR, Garrigues GE, Kowalsky M, Rubash HE, Shanbhag AS: Effects of bisphosphonates (alendronate and zoledronate) on bone ingrowth in a rabbit model: A radiographic and histomorphometric analysis. Trans Orthop Res Soc 2003; 27:1375.
53. Tonino RP, Meunier PJ, Emkey R, et al: Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 2000;85: 3109-3115.
54. Emkey R, Reid I, Mulloy A, et al: Ten-year efficacy and safety of alendronate in the treatment of osteoporosis in postmenopausal women. J Bone Miner Res 2002;(suppl):S1059.
55. Mundy G, Garrett R, Harris S, et al: Stimulation of bone formation in vitro and in rodents by statins. Science 1999;286:1946-1949.
56. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ: Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000;27:687-694.
57. Giuliani N, Pedrazzoni M, Negri G, Passeri G, Impicciatore M, Girasole G: Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone 1998;22:455-461.
58. Tsuchimoto M, Azuma Y, Higuchi O, et al: Alendronate modulates osteogenesis of human osteoblastic cells in vitro. Jpn J Pharmacol 1994;66:25-33.
59. von Knoch F, Jaquiery C, Kowalsky M, et al: Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials 2005;26:6941-6949.
60. Im GI, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS: Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 2004;25:4105-4115.
61. Bauer DC, Mundy GR, Jamal SA, et al: Statin use, bone mass and fracture: An analysis of two prospective studies. Bone 1999;14:S179.
62. Giuliani N, Girasole G, Pedrazzoni M, Passeri G, Gatti C, Passeri M: Alendronate stimulates b-FGF production and mineralized nodule formation in human osteoblastic cells and osteoblastogenesis in human bone marrow cultures. J Bone Miner Res 1995;10(suppl 1):S171.
63. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T: Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999; 104:1363-1374.
64. Burr DB, Miller L, Grynpas M, et al: Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs. Bone 2003;33:960-969.
65. Shanbhag AS, Rubash HE: Bisphosphonate therapy for the prevention of osteolysis in total joint replacements. Curr Opin Orthop 1998;9:81-87.
66. Fischer KJ, Vikoren TH, Ney S, et al: Mechanical evaluation of bone samples following alendronate therapy in healthy male dogs. J Biomed Mater Res B Appl Biomater 2006;76:143-148.
67. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ: Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997;100:1475-1480.